An interaction study with cimetidine and the new angiotensin II antagonist valsartan

European Journal of Clinical Pharmacology

Volumn 53, Issue 6, 1998, Pages 451-458

  Schmidt, E K ^a,b   Antonin, K H ^b,c   Flesch, G ^a   Racine Poon, A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Ciba Holding Deutschland GmbH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cimetidine; Valsartan

Indexed keywords

CIMETIDINE; VALSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIMETIDINE; CROSS-OVER STUDIES; DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; REFERENCE VALUES; TETRAZOLES; VALINE;

EID: 0031969656     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050406     Document Type: Article

References (45)

1. 1-receptor subtype. Br J Pharmacol 110: 761-771
2. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, de Gasparo M (1995) Valsartan: preclinical and clinical profile of an anthypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13: 230-250
3. Müller P, Flesch G, de Gasparo M, Turri M, Preiswerk G, Howald H (1993) Single and multiple-dose phase I trials with the angiotensin II antagonist valsartan. J Hypertens 11 [Suppl 5]: S459-S460
4. Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang Y-T, Gatlin M (1997) Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 19: 447-458
5. Markham A, Goa KL (1997) Valsartan (a review of its pharmacology and therapeutic use in essential hypertension). Drugs 54: 299-311
6. Cifcova R, Botteri F, Mann J, Thirlwell J, Oddou-Stock P (1997) Comparison of the angiotensin II antagonist valsartan with the β-blocker atenolol in patients with severe essential hypertension (abstract). Am J Hypertens 10: 114A
7. Shaheen O, Branch RA (1986) Pharmacokinetic drug interaction with cimetidine. J Pharmacol Exp Ther 20: 1-6
8. Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12: 321-366
9. van Crugten J, Bochner F, Keal J, Somogyi A (1986) Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236: 481-487
10. In: Hardman JG, Limbird LE (eds) (1996) Goodman and Gilman's The pharmacological basis of therapeutics. 9th edn. Pergamon Press, New York
11. Hansten PD (1991) Drug interactions with antisecretory agents. Aliment Pharmacol Ther 5 [Suppl 1]: 121-128
12. Feely J, Pereira L, Guy E, Hockings N (1984) Factors affecting the response to inhibition of drug metabolism by cimetidine dose response and sensitivity of elderly and induced subjects. Br J Clin Pharmacol 17: 77-81
13. Bartle WR, Walker SE, Shapero T (1983) Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther 33: 649-655
14. Patwardhan RV, Johnson RF, Sinclair AP, Schenker S, Speeg Jr KV (1981) Lack of tolerance and rapid recovery of cimetidine-inhibited chlordiazepoxide (Librium) elimination. Gastroenterology 81: 547-551
15. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27: 59-71
16. Somogyi A, Gugler R (1983) Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8: 463-495
17. Blume H, Mutschler E (eds) (1993) Bioäquivalenz - Qualitätsbewertung wirkstoffgleicher Fertigarzneimittel. Teil 2/1,4. Ergänzungslieferung. Govi, Frankfurt
18. Døssing M, Pilsgaard H, Rasmussen B, Engelhusen Poulsen H (1983) Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol 25: 215-222
19. Brunner LA, Powell ML, Degen P, Flesch G (1994) A semiautomated analytical method for the determination of potential antihypertensive agents (CGP 48933 and or CGP 48369) in human plasma using high-performance liquid chromatography. Lab Robotic Automation 6: 171-179
20. Sioufi A, Marfil F, Godbillon J (1994) Automated determination of an angiotensin II receptor antagonist, CGP 48933, in plasma by high-performance liquid chromatography. J Liquid Chromatogr 17: 2179-2186
21. Chiou R, Stubbs RJ, Bayne WF (1986) Determination of cimetidine in plasma and urine by high-performance liquid chromatography. J Chromatogr 377: 441-446
22. Strong HA, Spino M (1987) Highly sensitive determination of cimetidine and its metabolites in serum and urine by high-performance liquid chromatography. J Chromatogr 422: 301-308
23. Pidgen A (1996) Bioequivalence and generic prescribing: an industrial view. J Pharm Pharmacol 48: 11-16
24. Flesch G, Müller P, Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52: 115-120
25. Feiden K (ed) (1992) Arzneimittelprüfrichtlinien: Note for Guidance "Investigation of Bioavailability and Bioequivalence" (Rules Governing Medicinal Products in the European Community). 2nd Supplement. Wissenschaftliche Verlags-Gesellschaft, Stuttgart
26. Lin JH (1991) Pharmacokinetie and pharmacodynamic properties of histamine H2-receptor antagonists. Clin Pharmacokinet 20: 218-236
27. Martindale (1993) In: Reynolds JEF (ed.) The extra pharmacopoeia. 30th edn. Pharmaceutical Press, London pp 876
28. Oberle RL, Amidon GL (1987) The influence of variable gastricemptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15: 529-544
29. Gramatté T, El Desoky E, Klotz U (1994) Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 46: 253-259
30. Hunter J, Hirst BH (1997) Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Delivery Rev 25: 129-157
31. Mulkey PM, Murphy JE, Shleifer NH (1983) Steady-state theophylline pharmacokinetics during and after short-term cimetidine administration. Clin Pharm 2: 439-441
32. Greenblatt DJ, Abernethy DR, Morse DS, Harmatz JS, Shader RI (1984) Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 310: 1639-1643
33. Klotz, U, Reimann I (1980) Delayed clearance of diazepam due to cimetidine. New Engl J Med 302: 1012-1014
34. Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420
35. Colussi DM, Parisot C, Rossolino ML, Brunner LA, Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 37: 214-221
36. Feely J, Wilkinson GR, Wood AJJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692-695
37. Kochak GM, Rakhit A, Thompson TN, Hurley ME (1988) Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. J Clin Pharmacol 28: 222-227
38. Bauer LA, McDonnell N, Horn JR, Zierler B, Opheim K, Strandness DE (1990) Single and multiple doses of oral cimetidine do not change liver blood flow in humans. Clin Pharmacol Ther 48: 195-200
39. Reilly CS, Biollaz J, Koshakji RP, Wood AJJ (1986) Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism. Clin Pharmacol Ther 40: 37-41
40. Danzler WH, Wright SH (1997) Renal tubular secretion of organic anions. Adv Drug Delivery Rev 25: 217-230
41. Pritchard JB, Wright DS (1997) Renal secretion of organic cations: a multistep process. Adv Drus Delivery Rev 25: 231-242
42. DeAngelis C, Walker SE, Bartle WR (1983) Effect of low-dose cimetidine on theophylline metabolism. Clin Pharm 2: 563-567
43. Cohen IA, Johnson CE, Berardi RR, Hyneck ML, Achem SR (1985) Cimetidine-theophylline interaction: effects of age and cimetidine dose. Ther Drug Monit 7: 426-434
44. Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN (1984) Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Int Med 144: 484-486
45. Goldberg MR, Lo MW, Ritter MA, Höglund P (1995) Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 49: 115-119